+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oral Proteins and Peptides - Global Strategic Business Report

  • PDF Icon

    Report

  • 278 Pages
  • August 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6105952
The global market for Oral Proteins and Peptides was estimated at US$1.3 Billion in 2024 and is projected to reach US$2.0 Billion by 2030, growing at a CAGR of 7.4% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Oral Proteins and Peptides market.

Global Oral Proteins and Peptides Market - Key Trends & Drivers Summarized

Why Has Oral Delivery of Proteins and Peptides Remained Technically Difficult?

Proteins and peptides are sensitive biological molecules with poor intrinsic stability in the digestive system. When administered orally, they face rapid degradation by gastric enzymes and harsh pH conditions, followed by limited intestinal absorption due to large molecular size and hydrophilicity. These barriers have historically limited oral use of therapeutic proteins, pushing most into parenteral routes. However, recent scientific progress is making oral delivery more plausible, driving new investment in peptide-based oral drug development.

The motivation behind oral delivery is strong, particularly for long-term treatments like diabetes, growth disorders, and hormonal deficiencies. Patients prefer oral therapies over injections for convenience, comfort, and reduced risk of injection-related complications. Hence, the pharmaceutical industry is actively working on approaches to stabilize peptide structures and promote mucosal transport for systemic absorption.

What Formulation Techniques Are Enabling Systemic Uptake via the GI Tract?

Several formulation strategies are under active development to enable oral delivery of peptides and proteins. Use of enteric-coated capsules and enzyme inhibitors helps protect the drug until it reaches the intestine. Absorption enhancers such as medium-chain fatty acids and bile salts are employed to loosen tight junctions in the intestinal lining, temporarily increasing permeability. Carrier systems like nanoparticles, self-emulsifying drug delivery systems (SEDDS), and lipid-based formulations are designed to improve drug solubility and stability.

Technologies such as permeation-enhancing microcontainers, mucoadhesive films, and transcellular transporters are being refined to achieve consistent and safe absorption. Structural modification of peptides, including cyclization and D-amino acid substitution, improves resistance to enzymatic cleavage without affecting biological activity. These methods are allowing more peptide drugs to achieve bioavailability levels sufficient for therapeutic effect.

Which Therapies Are Leading in Development and Where Is Innovation Concentrated?

Diabetes and metabolic disorders are the leading therapeutic segments for oral peptide development. Oral semaglutide, a GLP-1 receptor agonist for type 2 diabetes, is the most notable commercial success, marking a breakthrough in this space. Similar efforts are targeting oral formulations of insulin, parathyroid hormone, and calcitonin for osteoporosis and thyroid-related disorders.

Biopharmaceutical companies are also exploring oral delivery of peptide-based immunotherapies and anti-inflammatory agents for conditions such as rheumatoid arthritis and ulcerative colitis. North America and select European countries are leading innovation due to strong R&D infrastructure and regulatory engagement. Emerging economies are watching closely for cost-effective formulations to broaden access.

Growth in the Oral Proteins and Peptides market is driven by several factors

Growth in the oral proteins and peptides market is driven by factors such as increasing demand for convenient alternatives to injectable biologics, progress in drug stabilization techniques, and growing therapeutic use of peptides in chronic diseases. Rising adoption of GLP-1 analogs and other metabolic treatments is fueling commercial interest in oral peptide delivery platforms.

Advancements in bioavailability enhancers, protective coatings, and intestinal absorption models are supporting wider application of peptide therapies in outpatient settings. Expansion of clinical pipelines, coupled with favorable patient preferences and emerging regulatory approvals, is creating a strong foundation for long-term market growth. Strategic partnerships between biotech firms and delivery technology companies are further accelerating the pace of innovation in this evolving field.

Scope Of Study:

The report analyzes the Oral Proteins and Peptides market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Drug Type (Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type, Plecanatide Drug Type); Application (Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application, Hormonal Disorders Application)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Calcitonin Drug Type segment, which is expected to reach US$762.5 Million by 2030 with a CAGR of a 6.1%. The Insulin Drug Type segment is also set to grow at 9.6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $351.6 Million in 2024, and China, forecasted to grow at an impressive 11.3% CAGR to reach $411.9 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Oral Proteins and Peptides Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Oral Proteins and Peptides Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Oral Proteins and Peptides Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as AbbVie Inc., Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Biocon Limited and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 32 companies featured in this Oral Proteins and Peptides market report include:

  • AbbVie Inc.
  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Chiasma Inc.
  • Entera Bio Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Nektar Therapeutics
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Protagonist Therapeutics, Inc.
  • Proxima Concepts Limited
  • Rani Therapeutics, LLC
  • Sanofi S.A.
  • Synergy Pharmaceuticals Inc.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Oral Proteins and Peptides - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Interest in Non-Invasive Biologic Delivery Spurs Innovation in Oral Protein and Peptide Formulations
  • Advancements in Permeation Enhancers Strengthen Business Case for Gastrointestinal Absorption Technologies
  • Surge in Oral GLP-1 Receptor Agonist Development Throws the Spotlight on Diabetes and Obesity Therapies
  • Increasing Focus on Enzyme and Hormone Replacement Expands Addressable Market for Oral Biologics
  • Progress in Nanotechnology and Carrier Systems Enhances Stability and Bioavailability of Oral Peptides
  • Use of Enteric Coating and Mucoadhesive Polymers Propels Controlled Release Formulation Development
  • Rising Investment in Oral Immunotherapy Supports New Pathways for Allergy and Autoimmune Treatment
  • Expansion of Biopharma Pipelines in Peptides Drives Demand for Alternative Drug Delivery Routes
  • Growing Application in Oncology and Rare Diseases Opens High-Value Market Segments for Oral Peptides
  • Technological Advances in Oral Nanocarriers Enhance Gastrointestinal Uptake and Therapeutic Impact
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Oral Proteins and Peptides Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Oral Proteins and Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Oral Proteins and Peptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Calcitonin Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Calcitonin Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Calcitonin Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Insulin Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Insulin Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Insulin Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Linaclotide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Linaclotide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Linaclotide Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Octreotide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Octreotide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Octreotide Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Plecanatide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Plecanatide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Plecanatide Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Bone Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Bone Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Bone Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Diabetes Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Gastric & Digestive Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Gastric & Digestive Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Gastric & Digestive Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hormonal Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hormonal Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Hormonal Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
CANADA
JAPAN
  • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
CHINA
  • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
EUROPE
  • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
FRANCE
  • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
GERMANY
  • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
ITALY
UNITED KINGDOM
  • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
AUSTRALIA
  • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Chiasma Inc.
  • Entera Bio Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Nektar Therapeutics
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Protagonist Therapeutics, Inc.
  • Proxima Concepts Limited
  • Rani Therapeutics, LLC
  • Sanofi S.A.
  • Synergy Pharmaceuticals Inc.

Table Information